Toxicological assessment of dihydroergotamine after chronic inhalation in dogs

Toxicologic Pathology

Volumn 39, Issue 3, 2011, Pages 544-552

  Armer, Thomas A ^a   Lynch, Maryellen ^b   Moutvic, Ronald ^b   Singer, Allen ^b  

^a MAP Pharmaceuticals Inc   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

dihydroergotamine; dog; inhalation; pulmonary; toxicity

Indexed keywords

DIHYDROERGOTAMINE; MAP 0004; UNCLASSIFIED DRUG;

ABRASION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; EXPERIMENTAL DOG; FEMALE; HISTOPATHOLOGY; HYPERSALIVATION; LARYNX SPASM; LOW DRUG DOSE; LUNG TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; SCABBING; SKIN MANIFESTATION; TREATMENT DURATION; VOMITING;

ADMINISTRATION, INHALATION; ANIMALS; DIHYDROERGOTAMINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; TOXICITY TESTS, CHRONIC;

CANIS FAMILIARIS;

EID: 79955565124     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311399786     Document Type: Article

References (27)

1. Aurora S. K., Rozen T. D., Kori S., Shrewsbury S. B.. A randomized, double blind, placebo controlled study of MAP0004 in adult patients with migraine. Headache. 2009 ; 49: 826-37
2. Cook R., Shrewsbury S., Ramadan N.. 5-HT, adrenergic, and dopaminergic receptor binding: Implications for inhaled dosing with dihydroergotamine mesylate via a novel system (Tempo Inhaler). Presented at the American Headache Society 49th Annual Scientific Meeting ; 2007 Chicago, IL ; 2007..
3. Cook R. O., Shrewsbury S. B.. Improved dihydroergotamine (DHE) pharmacology following orally inhaled delivery. Headache. 2008 ; 48: S55 - S56
4. Cook R. O., Shrewsbury S. B., Ramadan N. M.. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: Potential mechanism. Headache. 2009 ; 49: 1423-34
5. Novartis Pharmaceuticals, Inc ;
6. Galer B. S., Lipton R. B., Solomon S., Newman L. C., Spierings E. L.. Myocardial ischemia related to ergot alkaloids: A case report and literature review. Headache. 1991 ; 31: 446-50
7. Garcia G. D., Goff J. M., Hadro N. C., O'Donnell S. D., Greatorex P. S.. Chronic ergot toxicity: A rare cause of lower extremity ischemia. J Vasc Surg. 2000 ; 31: 1245-47 (Pubitemid 30418496)
8. Graham A. N., Johnson E. S., Persaud N. P., Turner P., Wilkinson M.. Ergotamine toxicity and serum concentrations of ergotamine in migraine patients. Hum Toxicol. 1984 ; 3: 193-99 (Pubitemid 14097953)
9. Harkema J. R.. Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants. Environ Health Perspect. 1990 ; 85: 231-38 (Pubitemid 20315302)
10. Washington, D.C: National Academy Press ; 1996 :
11. Labiris N. R., Dolovich M. B.. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003 ; 56: 600-12 (Pubitemid 37491711)
12. Lipton R. B.. Ergotamine tartrate and dihydroergotamine mesylate: Safety profiles. Headache. 1997 ; 37 (Suppl 1). S33 - S41
13. Little P. J., Jennings G. L., Skews H., Bobik A.. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol. 1982 ; 13: 785-90 (Pubitemid 13139859)
14. MaassenVanDenBrink A., Reekers M., Bax W. A., Ferrari M. D., Saxena P. R.. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998 ; 98: 25-30 (Pubitemid 28312075)
15. Magnoux E., Zlotnik G.. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache. 2004 ; 44: 249-55 (Pubitemid 38436688)
16. Molkara A. M., Abou-Zamzam A. M., Teruya T. H., Bianchi C., Killeen J. D.. Chronic ergot toxicity presenting with bilateral external iliac artery dissection and lower extremity rest pain. Ann Vasc Surg. 2006 ; 20: 803-8 (Pubitemid 46020511)
17. Müller-Schweinitzer E.. Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol. 1984 ; 26: 699-705 (Pubitemid 14074642)
18. Orton D. A., Richardson R. J.. Ergotamine absorption and toxicity. Postgrad Med J. 1982 ; 58: 6-11 (Pubitemid 12162590)
19. Saper J. R., Silberstein S.. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006 ;:
20. Saper J. R., Silberstein S., Dodick D., Rapoport A.. DHE in the pharmacotherapy of migraine: Potential for a larger role. Headache. 2006 ; 46 (Suppl 4). S212 - S20
21. Shrewsbury S. B., Cook R. O., Taylor G., Edwards C., Ramadan N. M.. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo) inhaler. Headache. 2008 ; 48: 355-67 (Pubitemid 351517766)
22. Shrewsbury S. B., Kori S. H., Miller S. D., Pedinoff A., Weinstein S.. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally inhaled DHE) in adult asthmatics. Curr Med Res Opin. 2008 ; 24: 1977-85
23. Shrewsbury S. B., Stonerook M., Okikawa J. K.. Intrapulmonary and intravenous administrations of dihydroergotamine mesylate (DHE) have similar cardiovascular effects in the conscious dog. Br J Pharmacol. 2008 ; 154: 1254-65 (Pubitemid 351992059)
24. Silberstein S. D., McCrory D. C.. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 ; 43: 144-66 (Pubitemid 36188447)
25. Suman J. D., Laube B. L., Dalby R.. Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. Pharm Res. 1999 ; 16: 1648-52 (Pubitemid 29510567)
26. Tay J. C., Chee Y. C.. Ergotism and vascular insufficiency: A case report and review of literature. Ann Acad Med Singapore. 1998 ; 27: 285-88 (Pubitemid 28293457)
27. Wong B. A.. Inhalation exposure systems: Design, methods and operation. Toxicol Pathol. 2007 ; 35: 3-14 (Pubitemid 46328404)